Connecticut 340B stakeholders testified at a state legislative hearing Monday on Gov. Ned Lamont’s (D) comprehensive bill to require hospital reporting on 340B revenue, prohibit drug maker restrictions on 340B contract pharmacy use, and prohibit pharmacy benefit manager discrimination against
…
The U.S. House Committee on Oversight and Accountability last week launched an investigation into how “anticompetitive tactics” by the three largest pharmacy benefit managers—Express Scripts, CVS Caremark, and OptumRx—are driving up healthcare costs and hurting patient care within federal health
…
Generic drug manufacturer Zydus Pharmaceuticals USA said in a recent public notice it will pay refunds for 340B overcharges that occurred mostly in the first two quarters of 2022. The products include Zydus’ equivalents of the widely prescribed antibiotic Zithromax,
…
Pharmaceutical Research and Manufacturers of America asked a U.S. appeals court in St. Louis, Mo. last week to strike down Arkansas’s first-of-its-kind 340B contract pharmacy law, arguing that it intrudes on the 340B statute and frustrates Congress’ intent to limit
…
National and state health center associations have filed amicus briefs in a lawsuit over California’s shift of Medicaid pharmacy benefits to Medicaid fee for service. They say the move will cost 340B providers in the state millions in savings needed
…
Legislation in Indiana that would have required hospitals to file annual reports disclosing their median reimbursement for 340B-priced drugs, along with numerous other financial disclosures, has failed to advance and has no chance of passage this year.
The wide-ranging hospital
…
Identical bills have been introduced in the Iowa House and Senate to bar pharmacy benefit managers and insurers from using alleged discriminatory practices against 340B covered entities and their contract pharmacies, including reimbursing them at a lower rate or imposing
…
Kansas lawmakers have introduced a bill to prohibit drug manufacturers from denying 340B covered entities access to a manufacturers’ products if the entities use contract pharmacies.
The legislation, like bills recently rolled out in other states, is modeled on the
…
The U.S. Department of Health and Human Services Office of the Inspector General says the Centers for Medicare and Medicaid Services should monitor non-hospital 340B covered entities’ use of modifiers to identify 340B-priced drugs in Part B claims, as these
…
The U.S. Senate committee with jurisdiction over 340B is officially under new leadership, with Bernie Sanders (I-Vt.) being seated as Health, Education, Labor, and Pensions chair last week and Bill Cassidy (R-La.) as ranking Republican.
The formal announcements had been
…*Sign up for news summaries and alerts from 340B Report